100 Technology Square, 5th Floor
About Magenta Therapeutics
Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics to reset the immune system to cure more patients with devastating and life-threatening diseases. This immune reset approach can be applied through stem cell transplant to multiple diseases, including autoimmune diseases, such as multiple sclerosis and systemic sclerosis; blood cancers, such as acute myeloid leukemia; and genetic diseases, such as sickle cell disease.
Magenta's comprehensive approach to precision immune system reset will transform many aspects of the transplant process, aiming to make it safer and more effective. Our culture is fueled by a driven, passionate group of people committed making a difference, seizing opportunities to make maximum impact and pursuing progress for the patients we seek to serve.
Stock Exchange: NASDAQ
Stock Symbol: MGTA
109 articles with Magenta Therapeutics
6/22/2018Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month.
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
Pricing of its initial public offering of 6,666,667 shares of its common stock at a price to the public of $15.00 per share, for total gross proceeds of approximately $100,000,000
Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients
6/8/2018Three clinical-stage biotechnology companies announced initial public offerings (IPOs) today. Here’s a summary.
5/29/2018It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
5/25/2018Weeks after securing $52 million in a Series C financing, Magenta Therapeutics is eying the raising of $100 million in an initial public offering two years after it was launched by Third Rock Ventures and Atlas Venture with $48.5 million in Series A financing.
Fresh off of striking a research deal with Ladenburg, Germany-based Heidelberg Pharma GmbH, Magenta Therapeutics secured $52 million.The funds will be used to advance Magenta's portfolio of bone marrow transplant medications.
-- Proceeds to support advancement of integrated portfolio of first-in-class therapeutics for bone marrow transplant --
Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors
Magenta Therapeutics announced the addition of Amy Ronneberg to its Board of Directors.
Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders
MGTA-456 is a first-in-class allogeneic stem cell therapy consisting of a single umbilical cord blood unit expanded with an aryl hydrocarbon receptor (AHR) antagonist then administered to a patient through a bone marrow transplant.
Magenta Therapeutics, a biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that chief operating officer Bastiano Sanna, Ph.D., has resigned from the Company, effective March 30, to pursue an opportunity outside of Magenta. Dr. Sanna has agreed to assist Magenta in an advisory capacity through the second quarter of 2018.
Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today announced the promotion of Christina Isacson, Ph.D. to chief business officer, and Tony Boitano, Ph.D. to vice president, stem cell biology.
Magenta Therapeutics is teaming up with Ladenburg, Germany-based Heidelberg Pharma to improve curative bone marrow transplantation.
Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates
Collaboration enables and accelerates Magenta’s research and development efforts across several targeted conditioning programs for bone marrow transplant; Expands application of Heidelberg Pharma ATAC technology to new targets
Magenta Therapeutics Presents Clinical and Preclinical Data at ASBMT Conference, Including New Preclinical Results on Microglial Engraftment with MGTA-456 Expanded Cord Blood Stem Cell Product
Five presentations of clinical and preclinical data from Magenta programs –Two presentations named among best in conference.
Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today announced that it has strengthened its clinical development team with the appointment of John Davis, MD, MPH, as chief medical officer.
Magenta Therapeutics announced the presentation of preclinical data from its hematopoietic stem cell (HSC) mobilization and expansion programs at the 59th annual meeting of the American Society of Hematology (ASH) in Atlanta, Ga.
Magenta's Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust Neutrophil and Immune Recovery in Two Phase II Clinical Studies
Data show rapid and durable engraftment with MGTA-456, an expanded cord blood stem cell product, in all 18 patients with hematologic malignancies across all conditioning regimens tested.
Magenta Therapeutics’ Lead Targeted Antibody Drug Conjugate Shows Promising Preclinical Results for Non-Genotoxic Conditioning for Bone Marrow Transplant
Magenta Therapeutics announced the presentation of preclinical data from its CD117 antibody-drug conjugate (ADC) conditioning program.